Shanghai Henlius Biotech, Inc.

SEHK:2696 Stock Report

Market Cap: HK$13.0b

Shanghai Henlius Biotech Management

Management criteria checks 2/4

Shanghai Henlius Biotech's CEO is Jason Zhu, appointed in Jul 2023, has a tenure of 1.42 years. total yearly compensation is CN¥9.26M, comprised of 87.8% salary and 12.2% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth HK$1.20M. The average tenure of the management team and the board of directors is 2 years and 5.3 years respectively.

Key information

Jason Zhu

Chief executive officer

CN¥9.3m

Total compensation

CEO salary percentage87.8%
CEO tenure1.4yrs
CEO ownership0.009%
Management average tenure2yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10
Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31
Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25
The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03
Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31
Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06
Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

CEO Compensation Analysis

How has Jason Zhu's remuneration changed compared to Shanghai Henlius Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CN¥692m

Mar 31 2024n/an/a

CN¥619m

Dec 31 2023CN¥9mCN¥8m

CN¥546m

Compensation vs Market: Jason's total compensation ($USD1.27M) is above average for companies of similar size in the Hong Kong market ($USD459.37K).

Compensation vs Earnings: Insufficient data to compare Jason's compensation with company performance.

CEO

Jason Zhu (46 yo)

1.4yrs

Tenure

CN¥9,261,000

Compensation

Dr. Jun Zhu, also known as Jason, had been Chief Financial Officer at Shanghai Henlius Biotech, Inc. since May 1, 2023 until July 1, 2024 and served as its President since November 30, 2021 until October 1...

Leadership Team

NamePositionTenureCompensationOwnership
Wenjie Zhang
Executive Chairman of the Board4.9yrsCN¥12.58mno data
Jun Zhu
CEO & Executive Director1.4yrsCN¥9.26m0.0092%
HK$ 1.2m
Huang Wei
President1.2yrsno datano data
Shi-Kau Liu
Co-founder & Head of Strategy Advisory Committee14.8yrsCN¥6.21m0.44%
HK$ 57.6m
Wei-Dong Jiang
Co-Founder & Co-Head of Innovative Advisory Committee14.8yrsno data0.13%
HK$ 17.2m
Yingbo Mao
VP & CFOless than a yearno datano data
Jifeng Zhang
CTO & Senior VP2yrsno datano data
Jijun Yuan
Chief Scientific Officerless than a yearno datano data
Miaojie Chen
Vice President of Legal & Compliance Department1.9yrsno datano data
Yan Wang
Deputy GM of Public Relations & Joint Company Secretary3.1yrsno datano data
Wallis Zeng
VP of Sales & Oncology Business Unit4.9yrsno datano data
Junhua Li
VP & Chief Human Resource Officer2.7yrsno datano data

2.0yrs

Average Tenure

53yo

Average Age

Experienced Management: 2696's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wenjie Zhang
Executive Chairman of the Board4.9yrsCN¥12.58mno data
Jun Zhu
CEO & Executive Director1.3yrsCN¥9.26m0.0092%
HK$ 1.2m
Tak Young So
Independent Non-Executive Director5.3yrsCN¥258.00kno data
Qiyu Chen
Non-Executive Director11.9yrsno datano data
Guoping Zhao
Independent Non-Executive Director5.3yrsCN¥258.00kno data
Xiaohui Guan
Non-Executive Director6yrsno datano data
K. Christopher Garcia
Member of Scientific Advisory Board1.4yrsno datano data
Yifang Wu
Non-Executive Director9.5yrsno datano data
Deyong Wen
Non-Executive Director2.4yrsno datano data
Lik Yuen Chan
Independent Non-Executive Director5.3yrsCN¥258.00kno data
Ruilin Song
Independent Non-Executive Director5.3yrsCN¥258.00kno data
Rongli Feng
Chairman of Supervisory Board4.7yrsno datano data

5.3yrs

Average Tenure

53yo

Average Age

Experienced Board: 2696's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Henlius Biotech, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang HuangBofA Global Research
Wangbin ZhouCitigroup Inc
Eva ZhaoCitigroup Inc